Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Vivo Bio Tech
|
Onyx Biotec
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
36.01 % | 7.43 % | 13.47 % |
|
5yr average Equity Multiplier
|
-0.87 | 2.24 | 2.51 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.43 | 0.82 |
|
5yr Avg Net Profit Margin
|
0.0 | 8.3 % | 6.72 % |
|
Price to Book
|
2.39 | 0.63 | 0.0 |
|
P/E
|
14.37 | 13.53 | 12.02 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 90.56 Days | 36.81 Days |
|
Inventory Days
|
0.0 | 72.05 Days | 48.71 Days |
|
Days Receivable
|
0.0 | 90.11 Days | 104.89 Days |
|
Days Payable
|
0.0 | 88.09 Days | 101.26 Days |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | 2.13 | 4.89 |
|
5yr Avg ROCE
|
21.53 % | 13.85 % | 12.63 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 39.67 % | 14.14 % |
|
5 yr average Debt to Equity
|
-1.45 | 1.08 | 0.95 |
|
5yr CAGR Net Profit
|
43.36 % | 5.09 % | 8.12 % |
|
5yr Average Return on Assets
|
-21.34 % | 3.6 % | 5.64 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 35.43 % | 65.1 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -6.65 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Vivo Bio Tech
|
Onyx Biotec
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|